Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study

被引:5
作者
Sang, Yuting [1 ,2 ]
Zhou, Xujie [1 ,2 ,3 ]
Chi, Weiru [1 ,2 ]
Chen, Jiajian [1 ]
Yang, Benlong [1 ]
Hao, Shuang [1 ]
Huang, Xiaoyan [1 ]
Liu, Guangyu [1 ,2 ]
Shao, Zhimin [1 ,2 ]
Wu, Jiong [1 ,2 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
国家重点研发计划;
关键词
breast cancer; neoadjuvant chemotherapy; surgery; mastectomy; breast conservation; oncoplastic surgery; LYMPH-NODE SURGERY; PATHOLOGICAL COMPLETE RESPONSE; ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; LOCOREGIONAL RECURRENCE; CONSERVATION THERAPY; CONSERVING SURGERY; AMERICAN-COLLEGE; TERM OUTCOMES; PRIMARY TUMOR;
D O I
10.3389/fonc.2022.984587
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNeoadjuvant chemotherapy (NAC) has evolved significantly and has been widely accepted for downstaging disease in early-stage and locally advanced breast cancer patients. Since the optimal surgical intervention for patients receiving NAC remains controversial, we aim to investigate the survival outcome of patients treated with different surgical management. MethodsA retrospective, nested case-control study was conducted in patients with invasive breast cancer that underwent NAC at Fudan University Shanghai Cancer Center from January 2010 to June 2019. Based on surgical intervention, patients were divided into mastectomy and breast conservation groups. Patients were matched on age at diagnosis, menopausal status, the year of the surgery, post neoadjuvant therapy pathological tumor (ypT) stage, post neoadjuvant therapy pathological node (ypN) stage, molecular subtypes, and axillary surgery by propensity score matching. ResultsA total of 2080 patients were enrolled in this study. Among them, 1819 (87.5%) patients were categorized as mastectomy group, and 261 (12.5%) patients were classed as breast conservation group. Over 9-years of research, the proportion of breast conservation steadily increased in patients after NAC. Data showed that younger (P<0.001) and pre-menopausal (P<0.001) patients with normal BMI (P=0.022) were more likely to receive breast conservation. Patients at advanced ypT stage (P<0.001), ypN stage (P<0.001), and clinical TNM stage (P<0.001) were more often to undergo mastectomy, while breast conservation rate was significantly higher in patients with triple-negative tumors (P=0.023). Compared with the mastectomy group, significant benefits in overall survival were observed in patients who received breast conservation (Hazard ratio 0.41, [95% confidence interval: 0.18-0.97]; p=0.049) in the matched cohort. There was no statistical difference between groups related to disease-free survival and locoregional recurrence. ConclusionsTumor biology can significantly impact the surgical decision in patients administrated with NAC. Breast conservation was a safe alternative for mastectomy in the NAC setting without compromising survival outcomes and locoregional control.
引用
收藏
页数:15
相关论文
共 63 条
  • [1] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
    Alberro, J. A.
    Ballester, B.
    Deulofeu, P.
    Fabregas, R.
    Fraile, M.
    Gubern, J. M.
    Janer, J.
    Moral, A.
    de Pablo, J. L.
    Penalva, G.
    Puig, P.
    Ramos, M.
    Rojo, R.
    Santesteban, P.
    Serra, C.
    Sola, M.
    Solarnau, L.
    Solsona, J.
    Veloso, E.
    Vidal, S.
    Abe, O.
    Abe, R.
    Enomoto, K.
    Kikuchi, K.
    Koyama, H.
    Masuda, H.
    Nomura, Y.
    Ohashi, Y.
    Sakai, K.
    Sugimachi, K.
    Toi, M.
    Tominaga, T.
    Uchino, J.
    Yoshida, M.
    Coles, C. E.
    Haybittle, J. L.
    Moebus, V.
    Leonard, C. F.
    Calais, G.
    Garaud, P.
    Collett, V.
    Davies, C.
    Delmestri, A.
    Sayer, J.
    Harvey, V. J.
    Holdaway, I. M.
    Kay, R. G.
    Mason, B. H.
    Forbe, J. F.
    Franci, P. A.
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 27 - 39
  • [2] APPROXIMATE CONFIDENCE-INTERVALS FOR PROBABILITIES OF SURVIVAL AND QUANTILES IN LIFE-TABLE ANALYSIS
    ANDERSON, JR
    BERNSTEIN, L
    PIKE, MC
    [J]. BIOMETRICS, 1982, 38 (02) : 407 - 416
  • [3] Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer-specific Mortality
    Arlow, Renee L.
    Paddock, Lisa E.
    Niu, Xiaoling
    Kirstein, Laurie
    Haffty, Bruce G.
    Goyal, Sharad
    Kearney, Thomas
    Toppmeyer, Deborah
    Stroup, Antoinette M.
    Khan, Atif J.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (12): : 1246 - 1251
  • [4] Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
    Ataseven, Beyhan
    Lederer, Bianca
    Blohmer, Jens U.
    Denkert, Carsten
    Gerber, Bernd
    Heil, Joerg
    Kuehn, Thorsten
    Kuemmel, Sherko
    Rezai, Mahdi
    Loibl, Sibylle
    von Minckwitz, Gunter
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1118 - 1127
  • [5] Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Bear, HD
    Anderson, S
    Smith, RE
    Geyer, CE
    Mamounas, EP
    Fisher, B
    Brown, AM
    Robidoux, A
    Margolese, R
    Kahlenberg, MS
    Paik, S
    Soran, A
    Wickerham, DL
    Wolmark, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2019 - 2027
  • [6] Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance)
    Boughey, Judy C.
    Ballman, Karla V.
    Le-Petross, Huong T.
    McCall, Linda M.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Taback, Bret
    Feliberti, Eric C.
    Hunt, Kelly K.
    [J]. ANNALS OF SURGERY, 2016, 263 (04) : 802 - 807
  • [7] Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)
    Boughey, Judy C.
    Ballman, Karla V.
    Hunt, Kelly K.
    McCall, Linda M.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Le-Petross, Huong T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3386 - +
  • [8] Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
    Boughey, Judy C.
    McCall, Linda M.
    Ballman, Karla V.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Taback, Bret
    Leitch, A. Marilyn
    Flippo-Morton, Teresa
    Hunt, Kelly K.
    [J]. ANNALS OF SURGERY, 2014, 260 (04) : 608 - 616
  • [9] Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
    Boughey, Judy C.
    Suman, Vera J.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Taback, Bret
    Leitch, A. Marilyn
    Kuerer, Henry M.
    Bowling, Monet
    Flippo-Morton, Teresa S.
    Byrd, David R.
    Ollila, David W.
    Julian, Thomas B.
    McLaughlin, Sarah A.
    McCall, Linda
    Symmans, W. Fraser
    Le-Petross, Huong T.
    Haffty, Bruce G.
    Buchholz, Thomas A.
    Nelson, Heidi
    Hunt, Kelly K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14): : 1455 - 1461
  • [10] C.o.B.C.S. Chinese Anti-Cancer Association, 2021, CHINA ONCOL, V31, P954